In hopeful news, AstraZeneca begins final trials of the Oxford University coronavirus vaccine which, if this trial is successful, could mean a vaccine before the end of the year (but only for the most at risk.)

In the third part of a drug trial, 50,000 people are getting the vaccine to test whether it can prevent people from getting the deadly virus. 30,000 of the volunteers are Americans.

Leading the charge is Oxford’s Professor Sarah Gilbert who said preliminary data from trials in these countries could be expected in the coming weeks.

AstraZeneca has cemented a deal with a UK company, plus manufacturers in China, the US, and across Europe so it could supply the entire world with the Oxford vaccine.